Gene · 478
ATP1A3: ATPase Na+/K+ transporting subunit alpha 3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ATP1A3: ATPase Na+/K+ transporting subunit alpha 3. Genes, record 478. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/478
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P13637 | Sodium/potassium-transporting ATPase subunit alpha-3 | 1,013 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents48
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| US 12533397 B2 | 2026-01-27 | 3 | P13637 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 38326 | P13637 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 25521 | P13637 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 499 | P13637 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 499 | P13637 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 25521 | P13637 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 7542 | P13637 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 24948 | P13637 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 24948 | P13637 | Espacenet |
| JP 2023548973 A | 2023-11-21 | 239 | P13637 | Espacenet |
1 to 10 of 48
See all 48 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ACETYLDIGITOXIN | CHEMBL3545057 | Sodium/potassium-transporting ATPase inhibitor | INHIBITOR | ChEMBL |
| DESLANOSIDE | CHEMBL1614 | Sodium/potassium-transporting ATPase inhibitor | INHIBITOR | ChEMBL |
| DIGITOXIN | CHEMBL254219 | Sodium/potassium-transporting ATPase inhibitor | INHIBITOR | ChEMBL |
| DIGOXIN | CHEMBL1751 | Sodium/potassium-transporting ATPase inhibitor | INHIBITOR | ChEMBL |
| ISTAROXIME | CHEMBL2093999 | Sodium/potassium-transporting ATPase inhibitor | INHIBITOR | ChEMBL |
| LANATOSIDE C | CHEMBL506569 | Sodium/potassium-transporting ATPase inhibitor | INHIBITOR | ChEMBL |
Trials55
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07272902 | DIGOXIN | ClinicalTrials.gov | ||
| NCT07047209 | DIGOXIN | PHASE2 | ClinicalTrials.gov | |
| NCT07025850 | DIGOXIN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06701812 | DIGOXIN | PHASE2 | ClinicalTrials.gov | |
| NCT06657404 | DIGOXIN | ClinicalTrials.gov | ||
| NCT06588699 | DIGOXIN | PHASE2 | ClinicalTrials.gov | |
| NCT06322017 | DIGOXIN | ClinicalTrials.gov | ||
| NCT06240403 | DIGOXIN | PHASE2 | ClinicalTrials.gov | |
| NCT06030622 | DIGOXIN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT05975021 | ISTAROXIME | PHASE1/PHASE2 | ClinicalTrials.gov |
1 to 10 of 55
See all 55 trialsNIH grants656
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ATP1A3 papers | Newest fiscal year |
|---|---|---|---|
| R01NS058949 | Clinical, Genetic, and Cellular Consequences of Mutations In NA,K-ATPase ATP1A3 | 27 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 3 | 2025 |
| R01AG067763 | Molecular characterization of extracellular vesicles for the spread of misfolded tau protein | 3 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 3 | 2025 |
| ZIANS002993 | Structure and Function of Membrane Proteins | 3 | 2025 |
| P30AG066518 | Oregon Alzheimer's Disease Research Center | 2 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 2 | 2025 |
| R01AG055909 | Probing Heterogeneity of Alzheimer's Disease Using iPSCs | 2 | 2025 |
| R01AG072719 | Assessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse model | 2 | 2025 |
| R01DC011805 | Imaging genetics of laryngeal dystonia | 2 | 2025 |
1 to 10 of 656Source NIH's project files
See all 656 nih grantsPapers1,199
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A De Novo ATP1A3 p.Arg995His Variant in a Patient With an Adult-Onset Primary Lateral Sclerosis-Like Syndrome. | Clin Genet | 2026 | 42823832 | PubTator, text mining | PubMed |
| Alternating Hemiplegia of Childhood: Development of a Disease-Specific Clinical Rating Scale. | Neurol Genet | 2026 | 42813040 | PubTator, text mining | PubMed |
| Scalable context-dependent single-cell eQTL mapping reveals disease-relevant regulatory variation beyond static models. | medRxiv | 2026 | 42780159 | PubTator, text mining | PubMed |
| Genetic Variants of Na+,K+-ATPase Associated With Neurological Disorders: A Systematic Review. | Am J Med Genet B Neuropsychiatr Genet | 2026 | 42764777 | PubTator, text mining | PubMed |
| Acute neuro-inflammatory presentation of ATP1A3 variants: Case reports of three patients with different phenotypes. | Arch Pediatr | 2026 | 42763957 | PubTator, text mining | PubMed |
| Monocular Nystagmus and Bulbar Dysfunction in Alternating Hemiplegia of Infantile Onset: A Novel Phenotype Associated with an ATP1A3 Mutation. | Ann Indian Acad Neurol | 2026 | 42734471 | PubTator, text mining | PubMed |
| Novel and Emerging Therapies for Childhood-Onset Movement Disorders. | Mov Disord | 2026 | 42723627 | PubTator, text mining | PubMed |
| Clinical and Genetic Spectrum of ATP1A3-Related Disorders: A Multicenter Cross-Sectional Study. | Neurol Genet | 2026 | 42666683 | PubTator, text mining | PubMed |
| [Clinical and genetic analysis of a child with Relapsing encephalopathy with cerebellar ataxia due to variant of ATP1A3 gene]. | Zhonghua Yi Xue Yi Chuan Xue Za Zhi | 2026 | 42386663 | PubTator, text mining | PubMed |
| The genetic landscape of childhood-onset dystonia in a nationwide Turkish cohort: Clinical spectrum, molecular diagnostics, and therapeutic implications. | Eur J Paediatr Neurol | 2026 | 42308683 | PubTator, text mining | PubMed |
1 to 10 of 1,199
See all 1,199 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/478
GET https://conductscience.org/api/genes/v1/478/patents?page=2